Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook

    Question

    Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook

    Direct answer

    Dentsply Sirona posted second-quarter adjusted EPS of $0.52, exceeding consensus expectations of $0.36 by $0.16. Although overall revenue fell 4.1% year-over-year, the Wellspect Healthcare division delivered 7.1% revenue growth. Management reiterated full-year 2026 net sales guidance of $3.5 billion to $3.6 billion and adjusted EPS guidance of $1.40 to $1.50, signaling confidence in cost discipline amidst medical equipment demand normalization.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-beats-q2-adjusted-eps-consensus-at-0-52-and-reaffirms-fy26-outlo-bcbbd6

    EQUITY
    Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook
    Dentsply Sirona posted second-quarter adjusted EPS of $0.52, exceeding consensus expectations of $0.36 by $0.16. Although overall revenue fell 4.1% year-over-year, the Wellspect Healthcare division delivered 7.1% revenue growth. Management reiterated full-year 2026 net sales guidance of $3.5 billion to $3.6 billion and adjusted EPS guidance of $1.40 to $1.50, signaling confidence in cost discipline amidst medical equipment demand normalization.
    XRAY
    Impact
    66
    SEP 9
    SIG
    85%
    XRAY
    Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook
    Dentsply Sirona posted second-quarter adjusted EPS of $0.52, exceeding consensus expectations of $0.36 by $0.16. Although overall revenue fell 4.1% year-over-year, the Wellspect Healthcare division delivered 7.1% revenue growth. Management reiterated full-year 2026 net sales guidance of $3.5 billion to $3.6 billion and adjusted EPS guidance of $1.40 to $1.50, signaling confidence in cost discipline amidst medical equipment demand normalization.
    → Stronger operational cost control offsets top-line declines, protecting Dentsply Sirona operating cash flow and reaffirming full-year EPS guidance.
    Impact
    Dentsply Sirona posted second-quarter adjusted EPS of $0.52, exceeding consensus expectations of $0.36 by $0.16. Although overall revenue fell 4.1% year-over-year, the Wellspect Healthcare division delivered 7.1% revenue growth. Management reiterated full-year 2026 net sales guidance of $3.5 billion to $3.6 billion and adjusted EPS guidance of $1.40 to $1.50, signaling confidence in cost discipline amidst medical equipment demand normalization.
    Affected
    XRAY
    Transmission
    Stronger operational cost control offsets top-line declines, protecting Dentsply Sirona operating cash flow and reaffirming full-year EPS guidance.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYearnings beat and FY2026 guidance reaffirmationUp1-5dAdjusted EPS of $0.52 beat $0.36 consensus; full-year guidance of $1.40-$1.50 EPS reaffirmed.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYUpdisagreed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month